SAN JOSE, Calif., Nov. 28, 2017 /PRNewswire/ -- ITUS
Corporation (NASDAQ: ITUS), a company using the power of the immune
system to diagnose and treat cancer, today announced that the
United States Patent and Trademark Office ("USPTO") has issued a
Notice of Allowance (NOA) on the second patent filed by the company
to protect its cancer detection technology. ITUS is
developing a platform called Cchek™ from which it expects to launch
a series of non-invasive, inexpensive diagnostic blood tests for
early cancer detection.
The patent is titled, "SYSTEMS AND METHODS USING ARTIFICIAL
NEURAL NETWORK ANALYSIS ON FLOW CYTOMETRY DATA FOR CANCER
DIAGNOSIS", and the inventors are Dr. Amit
Kumar, John Roop, and
Anthony Campisi. This patent
is assigned wholly to Anixa Diagnostics Corp. a wholly owned
subsidiary of ITUS Corporation.
Dr. Amit Kumar, ITUS's Chairman
and CEO, stated, "This is the second patent of our intellectual
property estate protecting our proprietary early cancer detection
technology. Our Cchek™ technology utilizes flow cytometry
analysis of circulating white blood cells and Artificial
Intelligence (Neural Network) to enable us to identify tumor
bearing patients. Unlike other technologies that seek to
identify DNA shed by tumors, or the tumor cells themselves that
might be circulating in blood, or other markers coming directly
from the tumor, our technology monitors subtle changes undergone by
the host immune system in a tumor bearing person. We have
already shown that these subtle changes are seen in 15 tumor types,
and we feel that this methodology will work for all tumor
types."
Dr. Kumar continued, "We are pleased to have received this
Notice of Allowance, as this enables us to take our existing
discussions with potential partners to the next level and to
initiate discussions with new potential partners. Receiving
the NOA is a major milestone in executing our business strategy of
establishing one or more partnerships to commercialize our
technology. Our goal is to work with partners who will
contribute their infrastructure and investment to aid us with
regulatory approvals as well as downstream commercialization
including manufacturing, sales, and marketing."
While the initial focus will be on confirmatory testing, ITUS
believes Cchek™ can eventually be used for multiple markets
including confirmatory testing, recurrence testing, therapy
monitoring, as well as screening. Existing confirmatory
diagnostics for many cancers rely on traditional biopsies, which
can be painful, expensive, and result in dangerous side effects.
ITUS hopes its unique liquid biopsy approach will significantly
improve upon current standards of care.
ITUS Corporation
ITUS, a cancer-focused biotechnology company, is harnessing the
body's immune system in the fight against cancer. Its wholly
owned subsidiary, Anixa Diagnostics Corporation, is developing the
CchekTM platform, a series of non-invasive blood tests
for the early detection of solid tumor based cancers, which is
based on the body's immunological response to the presence of a
malignancy. Its majority owned subsidiary, Certainty
Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs
which genetically engineer a patient's own immune cells to fight
cancer. ITUS also continually examines emerging technologies
in complementary or related fields for further development and
commercialization. Additional information is available at
www.ITUScorp.com.
Forward-Looking Statements: Statements that are
not historical fact may be considered forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical facts, but rather reflect ITUS Corporation's current
expectations concerning future events and results. We generally use
the words "believes," "expects," "intends," "plans," "anticipates,"
"likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We
undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You are
cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
ITUS Corporation: FOCUSED ON INNOVATION™
View original content with
multimedia:http://www.prnewswire.com/news-releases/itus-receives-notice-of-allowance-for-second-key-cancer-technology-patent-300562269.html
SOURCE ITUS Corporation